UK project to develop ‘cutting edge’ radiopharmaceuticals
A £19 million ($25 million) UK programme is set to power the recycling of nuclear materials to develop cutting edge treatments for cancer.
Led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), the project will use a radionuclide called lead-212 to create treatments called Targeted Alpha Therapies.
The programme will be backed by a £9.9 million ($13.3 million) investment from the Innovate UK Sustainable Medicines Manufacturing Innovation Programme (SMMIP), with a further £8.9m ($12 million) from industry.
While radionuclides are already used worldwide for medical scans to diagnose cancer and other conditions, Targeted Alpha Therapy is an innovative new application. Lead-212 could offer hope to patients with cancers that are currently hard to treat by targeting and destroying cancer cells with minimal damage to healthy tissue and reduced side effects.
“Almost 3.5 million people in the UK are living with cancer – but scientific breakthroughs are giving hope to more of them and their families,” said Science and Technology Secretary, Liz Kendall.
“It’s incredible to think that we could turn used nuclear fuel into cutting edge cancer treatments – but that is exactly what British scientific brilliance is making possible.
“Remarkable work like this, which could give cancer patients more priceless time with their loved ones, shows precisely why this government is giving record funding to research and development.”
Radiopharmaceuticals could ‘transform outcomes’ for cancer patients
UKNNL has developed a way to harvest a sustainable supply of lead-212 from recycled nuclear fuel, which has already been used to power homes across the country.
A tiny amount of lead-212’s parent material – equivalent to a single drop of water in an Olympic-sized swimming pool – is extracted through a series of chemical reactions. An even tinier amount of lead-212 is taken from this sample, which, when developed under the right conditions by scientists at MDC, could treat thousands of patients.
The UK has large reserves of lead-212, meaning that this approach could be scaled up to power new cancer treatments for patients in the UK and worldwide.
“Through access to the UK’s sovereign supply of lead-212, we have a truly unique opportunity to transform our nuclear expertise into life-saving cancer treatments,” added Julianne Antrobus, Chief Executive Officer at UKNNL.
“Developed from recycled fuel that has already served the nation by powering homes, lead-212 can now serve us again by offering new hope to cancer patients.
“UKNNL is proud to co-lead this pioneering programme alongside Medicines Discovery Catapult. By developing the infrastructure and processes to unlock the UK’s lead-212 supply, we’re not only advancing precision nuclear medicine but also reinforcing the UK’s position as a world leader in both nuclear science and healthcare innovation.
“This investment will help us deliver treatments that could transform outcomes for patients with previously untreatable cancers, both here in the UK and globally.”
